Evercore ISI's Mark Mahaney likes Meta, but says other names will give more upside
Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss the markets, Meta's historic winning ...
Fintel on MSN9h
Evercore ISI Group Upgrades CRISPR Therapeutics (CRSP)
Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...
PG&E price target lowered to $15 from $20 at Evercore ISI
Evercore ISI analyst Michael Lonegan lowered the firm’s price target on PG&E to $15 from $20 and keeps an In Line rating on the shares. The ...
Evercore ISI Remains a Hold on Tyler Technologies (TYL)
Evercore ISI analyst Kirk Materne maintained a Hold rating on Tyler Technologies (TYL – Research Report) yesterday and set a price target of ...
Evercore ISI Issues Positive Forecast for Confluent (NASDAQ:CFLT) Stock Price
Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...
Evercore ISI Boosts The Carlyle Group (NASDAQ:CG) Price Target to $52.00
The Carlyle Group (NASDAQ:CG – Get Free Report) had its price target hoisted by analysts at Evercore ISI from $51.00 to $52.00 in a report issued on Wednesday,Benzinga reports. The firm presently has ...
Investing on MSN7h
CRISPR Therapeutics stock rises following analyst upgrade
Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.